Connetics Corp.'s president and CEO Thomas Wiggans called it a "transforming event." Known for Olux and Luxiq, the marketed duo of foams to treat scalp disorders, his company this month entered an agreement to buy exclusive U.S. rights to F. Hoffmann-La Roche Ltd.'s marketed oral psoriasis drug, Soriatane, for $123 million. (BioWorld Financial Watch) Read More
